Moomoo AI 已提取核心訊息
BioVie Inc., a clinical-stage company focusing on the development of innovative drug therapies, has announced the offering of 15,000,000 shares of its Class A common stock at $1.00 per share, alongside pre-funded warrants to purchase up to 6,000,000 shares of common stock and warrants to purchase up to 10,500,000 shares of common stock. The pre-funded warrants are exercisable at $0.0001 per share, with a purchase price of $0.9999 each, and are immediately exercisable. The common warrants have an exercise price of $1.50 per share, are also immediately exercisable, and will expire five years from the issuance date. The shares and warrants are being sold together but will be issued separately and are immediately separable upon issuance. ThinkEquity LLC has been engaged as the exclusive...Show More
BioVie Inc., a clinical-stage company focusing on the development of innovative drug therapies, has announced the offering of 15,000,000 shares of its Class A common stock at $1.00 per share, alongside pre-funded warrants to purchase up to 6,000,000 shares of common stock and warrants to purchase up to 10,500,000 shares of common stock. The pre-funded warrants are exercisable at $0.0001 per share, with a purchase price of $0.9999 each, and are immediately exercisable. The common warrants have an exercise price of $1.50 per share, are also immediately exercisable, and will expire five years from the issuance date. The shares and warrants are being sold together but will be issued separately and are immediately separable upon issuance. ThinkEquity LLC has been engaged as the exclusive placement agent for the offering. The placement agent will use reasonable best efforts to arrange for the sale of the securities, but is not required to sell any specific number or dollar amount. The offering is expected to close on or about March 6, 2024, subject to customary closing conditions. The date of the prospectus supplement is March 4, 2024.
專注於創新藥物療法開發的臨床階段公司BioVie Inc. 宣佈以每股1.00美元的價格發行1500萬股A類普通股，同時發行購買最多600萬股普通股的預籌認股權證和購買最多1050萬股普通股的認股權證。預先注資的認股權證可按每股0.0001美元的價格行使，每份認股權證的收購價爲0.9999美元，可立即行使。普通認股權證的行使價爲每股1.50美元，也可以立即行使，並將自發行之日起五年內到期。股票和認股權證一起出售，但將分開發行，發行後可立即分離。ThinkEquity LLC已被聘爲本次發行的獨家配售代理。配售代理人將盡最大努力安排證券的出售，但無需出售任何特定數量或金額的證券。此次發行預計將於2024年3月6日左右結束，但須遵守慣例成交條件。招股說明書補充材料的發佈日期爲2024年3月4日。
專注於創新藥物療法開發的臨床階段公司BioVie Inc. 宣佈以每股1.00美元的價格發行1500萬股A類普通股，同時發行購買最多600萬股普通股的預籌認股權證和購買最多1050萬股普通股的認股權證。預先注資的認股權證可按每股0.0001美元的價格行使，每份認股權證的收購價爲0.9999美元，可立即行使。普通認股權證的行使價爲每股1.50美元，也可以立即行使，並將自發行之日起五年內到期。股票和認股權證一起出售，但將分開發行，發行後可立即分離。ThinkEquity LLC已被聘爲本次發行的獨家配售代理。配售代理人將盡最大努力安排證券的出售，但無需出售任何特定數量或金額的證券。此次發行預計將於2024年3月6日左右結束，但須遵守慣例成交條件。招股說明書補充材料的發佈日期爲2024年3月4日。
有用
沒用
